Hutchison China MediTech
Hong Kong, China

Hutchison China MediTech, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

Hutchison China MediTech (Chi-Med) has achieved the historic Chinese approval of fruquintinib, a first for a novel oncology drug discovered and developed solely in China. With this and its subsequent launch, the company accomplished a key goal, set at its foundation in 2000, of bringing the first of a wave of globally competitive products to market. Chi-Med is now firmly fixed on becoming a leading global biopharmaceutical company. It has a broad pipeline of first- or best-in-class clinical assets, in oncology and immunology, which together with well-established domestic sales forces, creates a powerful platform to market innovative products in China. Chi-Med is also taking first steps in building infrastructure to support commercialisation in the US and European markets. We value Chi-Med at £51.52/share or $33.49/ADS.

Market information

Symbol Exchanges Currency
Last Price Market Cap
52 Week Low 52 Week High


FY18 results as expected, plentiful news flow in FY19
Lighthouse | 11 Mar 2019
ASCO GU: promising PRCC data for savo/durva combo
Update | 20 Feb 2019
Global aspirations for a top-class Chinese innovator
Initiation | 06 Feb 2019

Recent News

2018 Final Results and Clinical Update
11 Mar 2019
Preliminary Phase II savolitinib/Imfinzi PRCC data at 2019 ASCO GU
12 Feb 2019
Savolitinib lung cancer progress and kidney cancer strategy update
20 Dec 2018
Amendment to 2013 Eli Lilly Fruquintinib License and Collaboration Deal
20 Dec 2018